Board Member
Fulcrum Therapeutics, Inc. (FULC)Equibles does not estimate personal net worth.
Get an email with a short summary when Fulcrum Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get FULC alertsAlex Sapir is recorded as Board Member at Fulcrum Therapeutics, Inc. (FULC) since June 17, 2024. Alex Sapir has spoken on 5 earnings calls across 1 company, most recently for Fulcrum Therapeutics, Inc. on April 27, 2026. Fulcrum Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Fulcrum Therapeutics, Inc. includes Alex C. Sapir (CEO and Board Member), Bryan Stuart (CEO, COO and Board Member), Robert J. Gould (CEO) and 7 others.
“The first quarter of 2026 was an important and exciting period for Fulcrum, highlighted by the positive clinical data we reported from the Phase I-B Pioneer trial of Posterior Deer in sickle cell disease.”
“So before jumping into the updates for the quarter, I just wanted to take a moment to welcome Dae Gon Ha, the newest member of the Fulcrum management team, as our Senior Vice President, Head of Strategy and Business Development.”
“The latter part of 2024 and early 2025 has been an exciting period for Fulcrum with notable progress for our lead program, pociredir, currently in development for the treatment of sickle cell disease.”
“I appreciate you joining us for our third-quarter conference call. Today, I'll provide you with updates on recent progress and upcoming milestones. I'll then hand the call over to Alan to review financials.”
“Thank you, Lisa, and good morning, everyone, and thanks to all of you for joining us for our second quarter conference call. We've organized today's call to provide you with updates on recent progress and upcoming milestones for our two clinical-stage assets, losmapimod and pociredir.”
2024-06-17–present
Biotechnology · Healthcare
Board Member
2024-06-17–present
